NEW YORK (GenomeWeb News) – BioFocus will offer its customers Activiomics' proteomics services for identifying novel biomarkers for diagnostics and targets for new drugs, the companies said today.

Under a strategic agreement, BioFocus will offer its customers Activiomics' Targeted In-depth QUAntification of cell Signaling, or TIQUAS, technology for proteomics studies in oncology, inflammation, and metabolic disease.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.